These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11585435)

  • 1. Preventive gynecologic surgery for BRCA1/2 carriers--information for decision-making.
    Quillin JM; Boardman CH; Bodurtha J; Smith T
    Gynecol Oncol; 2001 Oct; 83(1):168-70. PubMed ID: 11585435
    [No Abstract]   [Full Text] [Related]  

  • 2. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.
    Paley PJ; Swisher EM; Garcia RL; Agoff SN; Greer BE; Peters KL; Goff BA
    Gynecol Oncol; 2001 Feb; 80(2):176-80. PubMed ID: 11161856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complex decision-making for BRCA1/2 carriers.
    Matloff ET
    Cancer J Sci Am; 1999; 5(5):266-8. PubMed ID: 10526666
    [No Abstract]   [Full Text] [Related]  

  • 4. Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?
    Kauff ND; Barakat RR
    Gynecol Oncol; 2004 May; 93(2):277-9. PubMed ID: 15099933
    [No Abstract]   [Full Text] [Related]  

  • 5. BRCA: the breast, ovarian, and other cancer genes.
    Boyd J
    Gynecol Oncol; 2001 Mar; 80(3):337-40. PubMed ID: 11263927
    [No Abstract]   [Full Text] [Related]  

  • 6. Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy.
    Powell CB
    Gynecol Oncol; 2006 Jan; 100(1):1-2. PubMed ID: 16368438
    [No Abstract]   [Full Text] [Related]  

  • 7. A genetic epidemiological study of carcinoma of the fallopian tube.
    Aziz S; Kuperstein G; Rosen B; Cole D; Nedelcu R; McLaughlin J; Narod SA
    Gynecol Oncol; 2001 Mar; 80(3):341-5. PubMed ID: 11263928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of breast cancer in carriers of BRCA gene mutations.
    Birkmeyer JD; Welch HG
    N Engl J Med; 1997 Sep; 337(11):787-8; author reply 789. PubMed ID: 9289638
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
    Finch A; Shaw P; Rosen B; Murphy J; Narod SA; Colgan TJ
    Gynecol Oncol; 2006 Jan; 100(1):58-64. PubMed ID: 16137750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of breast cancer in carriers of BRCA gene mutations.
    Orlando R
    N Engl J Med; 1997 Sep; 337(11):787; author reply 789. PubMed ID: 9289637
    [No Abstract]   [Full Text] [Related]  

  • 11. Prophylactic surgery in patients with inherited risk of ovarian cancer.
    Morice P; Pautier P; Delaloge S
    Gynecol Oncol; 2001 Nov; 83(2):445-7. PubMed ID: 11606116
    [No Abstract]   [Full Text] [Related]  

  • 12. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy.
    Gynecol Oncol; 2005 Aug; 98(2):179-81. PubMed ID: 15979696
    [No Abstract]   [Full Text] [Related]  

  • 13. Hereditary breast cancer.
    Robson ME; Boyd J; Borgen PI; Cody HS
    Curr Probl Surg; 2001 Jun; 38(6):387-480. PubMed ID: 11375625
    [No Abstract]   [Full Text] [Related]  

  • 14. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?
    Olivier RI; Lubsen-Brandsma LA; van Boven H; van Beurden M
    Gynecol Oncol; 2005 Feb; 96(2):439-43. PubMed ID: 15661233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.
    Carcangiu ML; Peissel B; Pasini B; Spatti G; Radice P; Manoukian S
    Am J Surg Pathol; 2006 Oct; 30(10):1222-30. PubMed ID: 17001151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
    Finch A; Metcalfe KA; Chiang JK; Elit L; McLaughlin J; Springate C; Demsky R; Murphy J; Rosen B; Narod SA
    Gynecol Oncol; 2011 Apr; 121(1):163-8. PubMed ID: 21216453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
    Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report.
    Rose PG; Shrigley R; Wiesner GL
    Gynecol Oncol; 2000 May; 77(2):319-20. PubMed ID: 10785486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.
    Carcangiu ML; Radice P; Manoukian S; Spatti G; Gobbo M; Pensotti V; Crucianelli R; Pasini B
    Int J Gynecol Pathol; 2004 Jan; 23(1):35-40. PubMed ID: 14668548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast & ovarian cancer. Issues in risk assessment.
    Caro SW
    Adv Nurse Pract; 1999 Aug; 7(8):26-32; quiz 33-4. PubMed ID: 10745719
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.